NanoViricides

NNVC

Market cap $25.3M

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains its dual-track, rapid clinical development strategy for NV-387, going after MPox and also after all respiratory viral infections, that include Influenzas, Coronaviruses, RSV among others. The analyst research report was published by proactive investors news (https://www.proactiveinvestors.com/companies/news/1080303/nanoviricides-dual-track-clinical-development-during-2026-1080303.html/long).

Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2025 with the Securities and Exchange Commission (SEC) on Monday, September 29, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925094527/nnvc-20250630x10k.htm).

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA.

SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering ("LSX") World Congress 2025 in Boston, MA. Event Information: Event NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA Day & Date Wednesday, September 17, 2025 Time 12:30 pm Location LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.

NanoViricides (NYSE-A:NNVC) has highlighted the potential of its broad-spectrum antiviral NV-387 to address emerging COVID variants as cases of the new “Stratus” strain climb in California. The Stratus variant, a descendant of Omicron, now accounts for the vast majority of cases detected in wastewater, according to Los Angeles county health officials.

NanoViricides (NYSE-A:NNVC) said on Monday that its experimental broad-spectrum antiviral drug NV-387, now advancing into Phase II clinical trials, may help lower the risk of metastatic cancer returning in patients following viral infections. The company said recent studies have found that inflammation, particularly elevated levels of the cytokine IL-6 caused by infections such as COVID-19 and influenza, can reactivate dormant cancer cells, leading to the resurgence of metastatic disease.

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of "sleeping" cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials.

NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nations including the US, Canada, the UK, and the EU. The company said NV-387 has shown safety and effectiveness in preclinical studies using humanized mouse models and has completed a Phase I clinical trial with no reported adverse events, supporting its potential as a measles treatment.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.

NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in global pandemic preparedness. The Connecticut-based biotech firm said its NV-387 compound has demonstrated effectiveness in animal studies against a wide range of viral threats, including MPox, Smallpox, Measles, Influenza, Coronaviruses, and other orthopoxviruses.